ArticleBMC cancer2026
Pan-cancer analysis identifies KPNA7 as a prognostic and immune-related biomarker with functional relevance in gastric cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundKPNA7 modulated cellular functions via RNA interaction and had a crucial part in post-transcriptional gene expression regulation. However, the potential function played by KPNA7 in pan-cancer remained unclear.
methodsThe Cancer Genome Atlas (TCGA) was performed to study the expression of KPNA7 in normal and cancer tissues. Kaplan-Meier survival analysis and spearman correlation analysis were used to evaluate the associations of KPNA7 expression with prognosis, immune cell infiltration, tumor mutational burden (TMB) and microsatellite instability (MSI). We further investigated the relationship between KPNA7 expression levels and sensitivity to anticancer drugs. Finally, the effects of KPNA7 on gastric cancer cell proliferation, clonogenicity, migration, invasion, apoptosis, cell cycle, and in vivo tumor growth were evaluated using CCK-8, colony formation, scratch, transwell, flow cytometry, and subcutaneous xenograft assays.
resultsBioinformatic analyses showed that KPNA7 was overexpressed in multiple tumors and was associated with unfavorable survival in selected cancer types. KPNA7 expression was significantly correlated with immune-related features, including immune cell infiltration, immunomodulatory factors, TMB, and MSI in several cancers. In addition, KPNA7 expression was associated with anticancer drug sensitivity patterns. Functional experiments further showed that KPNA7 knockdown inhibited the proliferation, migration, and invasion of gastric cancer cells while promoting apoptosis.
conclusionThese findings suggested that KPNA7 may serve as a potential biomarker with tumor-type-specific prognostic and immune-related relevance in cancer, providing new insights into its possible value in cancer biology and therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.